GlycoMimetics to Present at BIO Investor Forum GAITHERSBURG, Md., Oct. 3, 2014 (GLOBE NEWSWIRE) -- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that CEO Rachel King will provide a company presentation at the 13th Annual BIO Investor Forum on...

GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel GAITHERSBURG, Md., Sept. 26, 2014 (GLOBE NEWSWIRE) -- GlycoMimetics, Inc. (Nasdaq:GLYC) announced today that it has been informed by Pfizer (NYSE:PFE), the company responsible for ongoing clinical...

GlycoMimetics to Present at BioCentury's 21st Annual Newsmakers in the Biotech Industry Conference GAITHERSBURG, Md., Sept. 22, 2014 (GLOBE NEWSWIRE) -- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Rachel King, Chief Executive Officer, will present an overview of the company at...

Data on GlycoMimetics' Drug Candidate's Potential to Treat Lung Infections Caused by Pseudomonas Aeruginosa to Be Presented at North American Cystic Fibrosis Conference GAITHERSBURG, Md., Sept. 8, 2014 (GLOBE NEWSWIRE) -- GlycoMimetics, Inc. (Nasdaq:GLYC) announced today that data from preclinical studies demonstrating the in vivo efficacy of GMI-1051, a drug...